Modelling the Effectiveness of Ibrutinib Versus Physician’s Choice (PC) in Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England
Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.249
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2017
Authors
Publisher
Elsevier BV